Toevoeging:
This will eventually become a hot topic of discussion. Unfortunately, nobody wants to address it now - too many gene editing investment dollars and valuations at play, despite clear ethical guidelines. When gene edited patients start coming down with cancer, the paradigm will shift. I always thought that gene editing companies would be tackling horrible diseases that other drugs could not properly address, instead, these gene editing companies are picking easy, low-hanging fruit targets to try and prove that their technology works, as it's too difficult for these companies to address the undruggable diseases that other drugs can't. Unfortunately, that low-hanging fruit has fantastic alternatives (i.e. RNAi, mRNA, ASO), as ethics are thrown out the door to give gene editing companies valuations that are going through the roof. Eventually, they will all collapse like a house of cards.
Dat laatste valt natuurlijk nog te bezien...